Search earnings tickers

ALNY

2024Q4BMO

Alnylam Pharmaceuticals Inc primary · HEALTHCARE · BIOTECHNOLOGY

Report 2025-02-13 · Fiscal end 2024-12-31 · Features as of 2025-02-12

← Earnings history

Street

Consensus EPS-0.14

Consensus rev—

EPS high—

EPS low—

Dispersion—

Analysts—

EPS rev net 7d—

EPS rev net 30d—

Consensus Δ 7d—

Consensus Δ 30d—

Options

Implied move3.0%

IV front—

P/C full—

P/C front—

Features as of2025-02-12

Run-up

Close—

Ret 5d-3.7%

Ret 10d-2.9%

Ret 20d+10.6%

Ret 30d+11.8%

Print

Actual EPS

0.06Beat

Estimated EPS-0.14

Actual revenue

593.2M

Surprise %+142.9%

Beat / missBeat

Beat streak 41

Beat streak 81

Reaction

1-day stock reaction+2.4%

Implied vs actual

Implied 3.0%Actual 2.8%

Gap reaction-2.8%

Day result-0.4%

Next-day upYes

Realized / IV0.92×

Post tape

Post 5d-5.4%

Post 10d-6.8%

Post volume769.2K

Vol ×10d1.20×

Vol ×20d1.13×

Post range4.6%